 | | | | Related Healthscout Videos | |
|
(Ivanhoe Newswire) -- A nationwide human papillomavirus (HPV) vaccination program for preadolescent girls may be a cost-effective idea, new research suggests. However, not all researchers think the program should be implemented.
After examining the health and economic outcomes of vaccinating 12-year-old girls and young women, researchers found the widespread vaccination of 12-year-olds could be cost-effective. However, calculations show a catch-up vaccination program for girls between the ages of 13 and 26 may not be a sound investment.
Text Continues Below
In calculations, researchers assumed the vaccine provided lifelong immunity.
The impact of the vaccine on cancer prevention and the duration of its effectiveness are yet to be determined. Study authors concluded decisions about an HPV vaccine policy will depend on future studies.
Charlotte Haug, M.D., Ph.D., author of the accompanying editorial, took a more defined view on the subject.
Despite great expectations and promising results of clinical trials, we still lack sufficient evidence of an effective vaccine against cervical cancer, Dr. Haug wrote.
She wrote that many questions remain unanswered about the vaccine, including how long it will last and whether or not it will affect a womans natural immunity against HPV.
The Centers for Disease Control and Prevention recommend girls ages 11 and 12 receive the HPV vaccine, which was approved by the Food and Drug Administration in 2006.
SOURCE: New England Journal of Medicine, 2008;359:821-832, 861
Sign up for a free weekly e-mail on Medical Breakthroughs called First to Know by clicking here.
This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.
|
